



CANCER DISCOVERY

Evolutionary Pathways in BRCA1-Associated Breast Tumors

Filipe C. Martins, Subhajyoti De, Vanessa Almendro, et al.

Cancer Discovery 2012;2:503-511. Published OnlineFirst April 10, 2012.

Updated Version Access the most recent version of this article at:
doi:[10.1158/2159-8290.CD-11-0325](https://doi.org/10.1158/2159-8290.CD-11-0325)

Supplementary Material Access the most recent supplemental material at:
<http://cancerdiscovery.aacrjournals.org/content/suppl/2012/06/04/2159-8290.CD-11-0325.DC2.html>
<http://cancerdiscovery.aacrjournals.org/content/suppl/2012/04/10/2159-8290.CD-11-0325.DC1.html>

Cited Articles This article cites 37 articles, 15 of which you can access for free at:
<http://cancerdiscovery.aacrjournals.org/content/2/6/503.full.html#ref-list-1>

Citing Articles This article has been cited by 1 HighWire-hosted articles. Access the articles at:
<http://cancerdiscovery.aacrjournals.org/content/2/6/503.full.html#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.


Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.

RESEARCH BRIEF

Evolutionary Pathways in BRCA1-Associated Breast Tumors

Filipe C. Martins^{1,4,5,10,11}, Subhajyoti De^{2,7,12},
Vanessa Almendro^{1,4,5,13}, Mithat Gönen¹⁴,
So Yeon Park^{15,16}, Joanne L. Blum¹⁷,
William Herlihy¹⁸, Gabrielle Ethington¹⁷,
Stuart J. Schnitt^{6,8}, Nadine Tung^{5,9},
Judy E. Garber^{3,4,5}, Katharina Fette⁹,
Franziska Michor^{2,7}, and Kornelia Polyak^{1,4,5,19}



ABSTRACT

BRCA1-associated breast tumors display loss of *BRCA1* and frequent somatic mutations of *PTEN* and *TP53*. Here we describe the analysis of *BRCA1*, *PTEN*, and *p53* at the single cell level in 55 *BRCA1*-associated breast tumors and computational methods to predict the relative temporal order of somatic events, on the basis of the frequency of cells with single or combined alterations. Although there is no obligatory order of events, we found that loss of *PTEN* is the most common first event and is associated with basal-like subtype, whereas in the majority of luminal tumors, mutation of *TP53* occurs first and mutant *PIK3CA* is rarely detected. We also observed intratumor heterogeneity for the loss of wild-type *BRCA1* and increased cell proliferation and centrosome amplification in the normal breast epithelium of *BRCA1* mutation carriers. Our results have important implications for the design of chemopreventive and therapeutic interventions in this high-risk patient population.

SIGNIFICANCE: Defining the temporal order of tumor-driving somatic events is critical for early detection, risk stratification, and the design of chemopreventive therapies. Our combined experimental and computational approach reveal that the loss of wild-type *BRCA1* may not be the first event in the majority of *BRCA1*-associated breast tumors and may not be present in all cancer cells within tumors. *Cancer Discov*; 2(6): 503–11. ©2012 AACR.

Authors' Affiliations: Departments of ¹Medical Oncology, ²Biostatistics and Computational Biology, and ³Radiation Oncology, Dana-Farber Cancer Institute; ⁴Department of Medicine, Brigham and Women's Hospital; Departments of ⁵Medicine and ⁶Pathology, Harvard Medical School; ⁷Department of Biostatistics, Harvard School of Public Health; Departments of ⁸Pathology and ⁹Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; ¹⁰Obstetrics and Gynaecology Department, Hospitais da Universidade de Coimbra, Coimbra, Portugal; ¹¹Gulbenkian Programme for Advanced Medical Education, Portugal; ¹²King's College, University of Cambridge, Cambridge, United Kingdom; ¹³Department of Medical Oncology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; ¹⁴Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York; ¹⁵Department of Pathology, Seoul National University College of Medicine, Seoul; ¹⁶Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, South Korea;

¹⁷Baylor–Charles A. Sammons Cancer Center; ¹⁸Department of Pathology, Baylor University Medical Center, Dallas, Texas; and ¹⁹Harvard Stem Cell Institute, Cambridge, Massachusetts

Note: Supplementary data for this article are available at Cancer Discovery Online (<http://cancerdiscovery.aacrjournals.org/>).

Corresponding Authors: Kornelia Polyak, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave. D740C, Boston, MA 02215. Phone: 617-632-2106; Fax: 617-582-8490; E-mail: Kornelia.polyak@dfci.harvard.edu; and Franziska Michor, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 450 Brookline Ave. CLS-11007, Boston, MA 02215. Phone: 617-632-5045; Fax: 617-632-2444; E-mail: michor@jimmy.harvard.edu.

doi: 10.1158/2159-8290.CD-11-0325

©2012 American Association for Cancer Research.

INTRODUCTION

BRCA1 germline mutations confer a high risk of breast and ovarian cancer. Somatic loss of the wild-type *BRCA1* allele is thought to be a rate-limiting initiating step of tumorigenesis (1). *BRCA1*-associated breast tumors also acquire additional somatic genetic events during their progression as mutations of *PTEN* and *TP53* are frequently observed in these cases (2). The *BRCA1* tumor suppressor gene is thought to be a prototypical cancer susceptibility gene insofar as the somatic loss of the wild-type allele, most commonly through LOH, is a required rate-limiting step of tumor initiation (1). However, multiple lines of evidence suggest that even normal cells of *BRCA1* mutation carriers often display an altered phenotype, indicating haploinsufficiency (3–5). For example, the distribution and characteristics of breast epithelial progenitors are altered in *BRCA1* mutation carriers, thereby potentially increasing the probability of neoplastic transformation (6, 7). The inability of normal cells to survive the acute loss of *BRCA1* (8) also suggests that the loss of wild-type *BRCA1* may not be the initiating step of tumorigenesis. Correlating with this, the loss of wild-type *BRCA2* was shown to be a relatively late event in pancreatic tumorigenesis of *BRCA2* mutation carriers (9). Furthermore, loss of wild-type *BRCA1* may only occur in preexisting *TP53* mutant foci in ovarian cancer (10), and preinvasive and invasive breast tumors in *BRCA1/2* mutation carriers display a high degree of heterogeneity for *BRCA1/2* LOH (11). Here we describe the analysis of *BRCA1*, *p53*, and *PTEN* at the single cell level and computational methods to identify the most likely evolutionary pathways in *BRCA1*-associated breast tumors.

RESULTS

To investigate the relative order of somatic loss of *PTEN*, *BRCA1* LOH, and mutation in *TP53* in *BRCA1*-associated breast tumors, we used a combined computational and experimental approach based on the following assumptions: (i) invasive tumors still contain cancer cells from earlier progression steps, (ii) if all tumor cells have mutation X but only a subset of them harbor mutation Y, then mutation X must have occurred before Y, (iii) the rate of cell proliferation and death is not significantly different between cells with single and combined alterations, (iv) by quantifying the number of tumor cells with single mutations and combinations thereof, the probable evolutionary path of a tumor can be identified, and (v) the analysis of a part of a tumor provides information about the whole. Thus, we analyzed the frequency of individual tumor cells with single and combined alterations in 55 malignant breast tumors from *BRCA1* germline mutation carriers (Supplementary Table S1). Because mutation detection by sequencing from single cells *in situ* in tissue slices is currently technically not feasible and silencing by DNA methylation or other epigenetic mechanisms may be an alternative mode of gene inactivation, we used a combination of immunofluorescence, immuno-FISH (FISH combined with immunofluorescence), and dual immunohistochemistry (IHC) for assessing the status of these 3 proteins at the single cell level in archived tissue samples. Specifically, the expression of *PTEN* was evaluated by IHC, *BRCA1* LOH by FISH (defining

LOH when both BAC and CEP signal counts \neq 2), whereas the mutational status of *p53* was evaluated by IHC (when combined with immunostaining for *PTEN*) or by immunofluorescence (when combined with *BRCA1* FISH).

Assays were optimized using xenografts and formalin-fixed paraffin-embedded (FFPE) cell blocks derived from breast cancer cell lines with known *PTEN*, *TP53*, and *BRCA1* status, and also sections from mice with conditional deletion of *PTEN* in the prostate epithelium (12) as the antibody used also detects mouse *PTEN* (Supplementary Fig. S1A–C and Supplementary Table S2), followed by testing of sporadic breast tumor samples. The *PTEN* antibody used has been previously validated in *BRCA1*-associated breast tumors for specificity for wild-type *PTEN* (13). Staining in genetically normal stromal cells was used as an internal control on each tumor section. Each of these methods has limitations, such as the inability to detect all *TP53* mutations by IHC and the limited accuracy to predict loss of wild-type *BRCA1* allele by FISH. On the other hand, by assessing proteins instead of mutations in DNA, nongenetic causes of *PTEN* inactivation or activation of *p53* signaling could also be detected. To assess our accuracy of predicting *BRCA1* LOH based on FISH, we analyzed a set of slides derived from cell lines with wild-type or mutant *BRCA1* mixed at different ratios (10%, 25%, and 40%) and found good agreement ($D = 0.85$, Somer D) between the predicted and known *BRCA1* LOH percentage (Supplementary Fig. S1D). To estimate the concordance between results obtained using methods we employed for single-cell analysis and those used for bulk cell populations, we compared *BRCA1* LOH frequencies estimated based on FISH to that based on PCR analysis of laser capture microdissection-purified tumor cells (14). By using certain assumptions and converting PCR values to the number of mutant alleles (details in Methods and in Supplementary Table S3) using the Dixon Q test (15), we only detected 4 outliers (36 tumors analyzed by both methods), in which the 2 techniques led to different results; this finding was potentially due to uniparental isodisomy for the *BRCA1* locus in these cases. Excluding these 4 cases, the percentage of cells with *BRCA1* LOH inferred by FISH was on average 12.7% lower than that inferred by PCR, and the average difference between the 2 techniques was only 20.5% ($\pm 13.3\%$; Supplementary Fig. S1E). Therefore, despite the technical limitations of methods applicable for the analysis of single cells *in situ* in intact tissues, the obtained results are in good agreement with those using other current technologies. Nevertheless, mutational analysis of single cells *in situ*, which may be feasible in the future, would likely give the most accurate results.

Next, we analyzed 55 *BRCA1*-associated and 20 sporadic breast tumors from women with no family history of breast cancer (Fig. 1A and Supplementary Tables S1 and S4). We counted 100 to 200 individual cancer cells in each tumor, and for each cell, we recorded the status of all 3 genes (i.e., wild-type = wt and mutant = mut; details of counting are described in Methods section). Thus, each cell belonged to 1 of 8 possible states (i.e., $PTEN_{wt}TP53_{wt}BRCA1_{wt}$, $PTEN_{wt}TP53_{wt}BRCA1_{mut}$, $PTEN_{wt}TP53_{mut}BRCA1_{wt}$, $PTEN_{wt}TP53_{mut}BRCA1_{mut}$, $PTEN_{mut}TP53_{wt}BRCA1_{wt}$, $PTEN_{mut}TP53_{wt}BRCA1_{mut}$, $PTEN_{mut}TP53_{mut}BRCA1_{wt}$, and $PTEN_{mut}TP53_{mut}BRCA1_{mut}$). For each tumor, we recorded the number of cells in each state (Supplementary Table S1). To determine the most probable first mutation




Figure 1. Evolutionary pathways in BRCA1-associated breast tumors. **A**, examples of immuno-FISH and immunohistochemical analyses. **B**, predicted order of somatic events and tumor characteristics. Bars mark loss of PTEN (green), BRCA1 LOH (brown), and mutation of p53 (orange). Hormone receptor (ER and PR) and HER2 status, presence of PIK3CA mutation (*), and probable evolutionary pathways (Path 1 and Path 2) are indicated. In a few tumors both evolutionary paths were observed (T5, T24, and T44), whereas a few others could not be assigned to either path at high confidence. T30# is a ductal carcinoma *in situ* (DCIS). **C**, summary of evolutionary paths in BRCA1-associated breast tumors. The thickness of the arrows and size of the circles are proportional to the number of tumors (indicated within circles and next to arrows) following the depicted paths. Blue and red indicate luminal and basal-like tumors, respectively. The 3 main paths are depicted by dashed red (basal-like tumors) and blue (mainly luminal tumors) arrows.

event, we then compared the numbers of cells belonging to the 3 single-mutation states—for instance, $PTEN_{wt}TP53_{wt}BRCA1_{mut}$, $PTEN_{wt}TP53_{mut}BRCA1_{wt}$, and $PTEN_{mut}TP53_{wt}BRCA1_{wt}$ —and determined whether any state had a significantly higher number of cells compared with the 2 other states (Supplementary Table S3, see Methods for details). The state with the larger number of cells was then designated as indicating the first event. Once the first event was determined, we compared the cell counts of the remaining 2 mutational states in a similar manner to determine the most probable second event. If a sample contained any cells with all 3 mutations, then we identified the mutation of the third gene as the last event. For most samples, the order of events was determined unambiguously, whereas for a few samples, the cell counts of the 8 states suggested complex evolutionary trajectories.

Using this approach, we found that there were 2 main evolutionary pathways in BRCA1 tumors defined by the presence or absence of PTEN. In the majority (28 of 55) of tumors, loss of PTEN was the most probable first event, followed by mutation in *TP53* or *BRCA1* LOH with about equal probability (Fig. 1B). Mutation in *TP53* was the second most common first event detected in 17 of 55 cases, and it was almost always followed by *BRCA1* LOH. *BRCA1* LOH was the least common first event, observed in only 10 of 55 tumors, and the majority of these cases had mutant p53 as the only other alteration. The relative order of events and thus evolutionary paths to tumorigenesis were strongly associated with the tumor subtype,

as triple negative [i.e., negative for estrogen receptor (ER) and progesterone receptor (PR) and HER2; $ER^{-}/PR^{-}/HER2^{-}$] tumors almost always had PTEN loss as the first event (path 1), whereas luminal tumors showed mutant *TP53* or *BRCA1* LOH as the first event (path 2; Fig. 1C). We categorized all tumors with PTEN loss as the first event into path 1, regardless of their *TP53* status on the basis of IHC because some *TP53* mutations, such as protein truncation, cannot be detected by the antibody-based technology we used (16). In 3 tumors, we found evidence for both evolutionary paths; thus, these samples could not be unambiguously assigned to either trajectory (Fig. 1B and Supplementary Fig. S2A). In addition, we cannot exclude the possibility of other mutational events taking place that could define different evolutionary paths. Interestingly, all commonly used BRCA1 mutant breast cancer cell lines (HCC-1937, MDA-MB-436, SUM-1315, and SUM-149) are triple negative with loss of PTEN and mutant *TP53* and all other PTEN null cell lines also have *TP53* mutations (13), implying a selective advantage of clones with a combination of these changes both *in vivo* in the tumors from which the cell lines were derived and in cell culture.

As opposed to the BRCA1-associated hereditary cases, loss of PTEN was detected at lower frequency in sporadic triple-negative breast tumors (Supplementary Table S3). Allelic imbalance of the *BRCA1* locus was also rarely (<5%) observed in sporadic cases (Supplementary Tables S3 and S4) and due to the lack of germline mutation, it is not equivalent to *BRCA1* LOH in BRCA1-linked tumors. In sporadic breast

tumors, PTEN loss and *PIK3CA* mutations are associated with the basal-like and luminal subtypes, respectively (17). In our *BRCA1*-associated patient cohort, PTEN loss was strongly associated with ER status ($P = 5.36 \times 10^{-7}$, Fisher exact test; Supplementary Table S5) and even in the luminal tumors, the percentage of ER⁺ tumor cells was lower than in sporadic cases ($P = 0.01$, Mann-Whitney test; Supplementary Tables S1 and S4). All but one ER⁺ tumor (a DCIS) expressed wild-type PTEN, whereas most ER⁻ tumors were PTEN negative. To determine whether *PIK3CA* mutation may be an alternative mechanism to PTEN loss for the activation of the PIK3CA/AKT pathway in *BRCA1* luminal tumors (though loss of PTEN and mutation in *PIK3CA* are not functionally equivalent), we assessed the most common mutational hotspots in *PIK3CA* (E542K, E545A, E545K, H1047L, and H1047R) by mass spectrometry (18). Only 2 of 55 *BRCA1* tumors (one ER⁺ and one ER⁻) but 6 of 10 luminal and none of 10 triple-negative sporadic tumors had mutant *PIK3CA* (Supplementary Tables S1 and S4), suggesting that even luminal *BRCA1* tumors display tumorigenic paths distinct from those of sporadic cases. These results also implied that these luminal breast tumors observed in *BRCA1* mutation carriers are not likely to be sporadic cases.

Our findings were intriguing: the loss of wild-type *BRCA1* may not be the first event in most *BRCA1*-associated breast tumors, and even in tumors that display apparent loss of the wild-type *BRCA1* allele, not all tumor cells showed this change (Fig. 2A and B). We thus investigated these findings in further detail. First, we analyzed whether the intratumor frequency of *BRCA1* LOH and the intratumor diversity in cell types were associated with tumor subtype and evolutionary paths. Interestingly, the percentage of tumor cells with *BRCA1* LOH was significantly higher ($P = 0.047$, Mann-Whitney test) in basal-like tumors for which loss of PTEN was the first event (Fig. 2B). To assess associations between evolutionary paths and intratumor diversity for *BRCA1* LOH, we grouped the tumor samples according to the probable first event (i.e., *PTEN*, *BRCA1*, or *TP53* mutation) and plotted the distribution of Shannon and Simpson indices for each group (Supplementary Table S1); these indices are routinely used in evolutionary biology and ecology to determine species diversity (19). In general, the samples in which *BRCA1* LOH was the most probable first event had a greater extent of diversity, whereas the opposite (lower diversity) was observed in tumors with *TP53* mutation as first event, although neither of these was statistically significant (Fig. 2C).

Next, we sought to confirm the presence of functional wild-type *BRCA1* protein in tumors with heterogeneous *BRCA1* LOH based on FISH. Thus, we carried out immunofluorescence analysis of *BRCA1* in all tumors and analyzed foci formation in S-phase cells, which is regarded as definitive evidence for wild-type *BRCA1* (20). We found a good agreement between the FISH and immunofluorescence data ($D = 0.98$, Somer D ; Supplementary Table S1 and Supplementary Fig. S2B), and *BRCA1* foci were readily observed in cells of tumors with heterogeneous but not with complete loss of *BRCA1* (Fig. 2D and Supplementary Fig. S2C). We validated the functional relevance of the *BRCA1* foci we observed by confirming their colocalization with Rad51 (Supplementary Fig. S2D).

Our finding that loss of *BRCA1* is rarely the first event in *BRCA1*-associated breast tumors suggested a haploinsufficient phenotype in the mammary epithelium that may explain

the increased risk for breast cancer in mutation carriers. For example, the number of cell-of-origin for breast cancer might be higher in *BRCA1* mutation carriers, contributing to their higher risk of breast cancer (21). Correlating with this, we (Su and colleagues; unpublished data) and others (6, 7) have observed that the relative fraction of breast epithelial progenitors is higher in *BRCA1* mutation carriers compared with control women, potentially implying a higher rate of cell proliferation in mutation carriers. Estrogen and progesterone are potent mitogens for normal breast epithelial cells and prior studies in *Brca1*^{-/-} mice showed that blocking progesterone signaling inhibits mammary tumorigenesis (22). Thus, we analyzed the number of breast epithelial cells positive for Ki67, a proliferation marker, and for PR by multi-color immunofluorescence in control and *BRCA1* tissues. We detected significantly more Ki67⁺, PR⁺, and Ki67⁺PR⁺ cells in contralateral normal breast tissue of *BRCA1* mutation carriers diagnosed with breast cancer compared with that observed in controls, whereas normal prophylactic mastectomy tissues of *BRCA1* mutation carriers without breast cancer and reduction mammoplasty tissue from controls were not significantly different (Fig. 3A and B and Supplementary Table S6). The percentage of PR⁺ and Ki67⁺ cells fluctuates during the menstrual cycle with higher fraction of cells being positive in the luteal phase of the menstrual cycle. However, it is unlikely that all control and all *BRCA1* mutation carriers would be in the same phase of their cycle leading to the observed differences.

During the analysis of Ki67⁺ cells, we noticed occasional multipolar mitoses in normal breast tissues from *BRCA1* mutation carriers, suggesting aberrant centrosome function (Fig. 3C). Thus, we analyzed the number of centrosomes in the normal breast epithelium of *BRCA1* mutation carriers with and without breast cancer and that of matched controls by immunofluorescence for polyglutamylated tubulin, a centrosome marker (23). We found significantly higher ($P \leq 0.01$) numbers of cells with more than 2 centrosomes in *BRCA1* mutation carriers compared with controls (Fig. 3D and E).

DISCUSSION

The development of most human tumors is predicted to take many years and require the progressive accumulation of tumor-driving somatic alterations (24). Identification of genes and pathways that play key roles in tumor initiation and progression is the necessary first step toward designing therapies that may interfere with them, which would be especially important in germline mutation carriers of high-risk cancer susceptibility genes. Unfortunately, most human tumors are diagnosed at a relatively late stage, when they already accumulated numerous genetic and epigenetic alterations, making it difficult to decipher which one(s) are functionally relevant for tumorigenesis and at what progression stage. To address this issue, several mathematical models have been developed for predicting the relative order of somatic genetic alterations during tumor progression, including profiling tumors at different stages (25) and inferring the order of events based on cross-sectional genomic data of late-stage tumors (26, 27). We have investigated putative evolutionary pathways in *BRCA1*-associated breast tumors by assessing the status of *BRCA1*, PTEN, and p53




Figure 2. Heterogeneity for loss of wild-type *BRCA1* allele in *BRCA1*-associated breast tumors. **A**, representative immuno-FISH analysis for mutant p53 (blue), chromosome 17 CEP (green), and *BRCA1* BAC (red) probes depict heterogeneity for *BRCA1* copy number among individual cancer cells. Insets highlight 3 cells with different BAC to CEP signal ratios corresponding to normal and copy number gain and loss. **B**, intratumor diversity for *BRCA1* LOH. Frequency of tumor cells with *BRCA1* LOH and Shannon and Simpson indices of diversity in each of the 55 *BRCA1* tumors analyzed. The Pearson correlation coefficient between Shannon and Simpson indices is -0.9186 . The anticorrelation is not surprising because a population with a high Shannon index would usually have a low Simpson index and vice versa. **C**, associations between first event and frequency of *BRCA1* LOH and diversity indices. **D**, representative immunofluorescence analyses of *BRCA1* in tumors in which *BRCA1* foci are observed (top) or completely absent (bottom), indicating wild type and loss of function, respectively. Arrows mark leukocytes that serve as internal positive control.

at the single cell level and predicting the probable order of events using a statistical model based on the frequency of cells with single and combined alterations.

Following the Knudson 2-hit model for familial cancer syndromes (28), loss of wild-type *BRCA1* allele is presumed to be an essential rate-limiting step of *BRCA1*-associated tumorigenesis. However, several lines of evidence suggest that even the normal breast tissue of *BRCA1* germline mutation carriers display an abnormal phenotype including altered fre-

quency, gene expression profiles, and functional properties of breast epithelial progenitors (6, 7) that may increase the risk of breast cancer. Our result that loss of *PTEN* and *TP53* mutation occur before *BRCA1* LOH in most cases support the idea of a haploinsufficient phenotype in the normal breast epithelium of *BRCA1* mutation carriers. Even in tumors in which *BRCA1* LOH is the probable first event, not all tumor cells seem to have this alteration, potentially suggesting the presence of not-yet-identified somatic genetic (or epigenetic) alterations that




Figure 3. Abnormalities in the normal breast epithelium of *BRCA1* mutation carriers. **A**, representative examples of Ki67 and PR immunofluorescence in normal breast tissue from *BRCA1* mutation carriers and noncarrier controls. **B**, frequency of Ki67- and PR-positive cells in the same tissues. **C**, representative examples of multipolar mitoses in normal breast tissue from 2 distinct *BRCA1* mutation carriers. **D**, representative examples of polyglutamylated tubulin immunofluorescence in normal breast tissue from *BRCA1* mutation carriers and noncarrier controls. **E**, number of centrosomes per cell in the same tissues.

may precede the loss of wild-type *BRCA1* in these tumors. Our finding of increased cellular proliferation and abnormal mitoses coupled with centrosome amplification in normal breast epithelium of *BRCA1* mutation carriers further support a haploinsufficient phenotype that may increase breast cancer risk.

The first hint suggesting that *BRCA1* may regulate genomic instability by influencing centrosome function was its centrosomal localization in mitosis (29), which is maintained throughout the cell cycle, albeit at lower concentrations (30). Mammary tumors in mice with conditional deletion of *Brca1* exhibit gross genomic instability and centrosome amplification with recurrent genomic imbalances resembling those in human *BRCA1*-associated breast cancer (31). Studies in human breast cancer cell lines also showed that centrosome numbers are regulated by a *BRCA1*-dependent ubiquitination (32) and that expression of an enzymatically inactive *BRCA1* mutant leads to supernumerary and hyperactive centrosomes (30). However, as all these prior studies used cells completely devoid of wild-type *BRCA1*, our results are the first demonstration of centrosome abnormalities in the normal breast epithelium of *BRCA1* mutation carriers implying haploinsufficient phenotype for this function. The high frequency of *PTEN* loss by gross genomic rearrangements (13) and trun-

cating mutations in *TP53* in *BRCA1*-associated breast tumors (16) could potentially be due to genomic instability induced by abnormal centrosomes.

Our analysis of the probable order of loss of wild-type *BRCA1*, *PTEN*, and *TP53* also allows predictions about possible interactions among these tumor suppressor pathways. For example, in *BRCA1* tumors with both *PTEN* loss and *p53* mutation, the former was always predicted to precede the latter. Indeed, prior studies have described complex cooperative interactions between *PTEN* and *TP53* (33) that could lead to selection against loss of wild-type *PTEN* in cells with mutant *TP53*. The near-complete lack of *PIK3CA* mutations in *BRCA1*-associated tumors also implies that some genetic changes that commonly occur in sporadic breast tumors may not confer advantage during *BRCA1*-driven tumorigenesis, possibly due to differences in cell-of-origin or presence of other genetic or epigenetic alterations.

Our results have several potentially important clinical implications. First, PARP inhibitors are promising new agents for the treatment and prevention of tumors in *BRCA1* and *BRCA2* mutation carriers due to their synthetic lethal interaction in cells lacking wild-type *BRCA*-associated DNA repair function (34, 35). However, our data showing that loss of wild-type *BRCA1* may not be the first event in most *BRCA1*-associated breast tumors

and that this loss may not occur in all tumor cells raises concerns about the efficacy of such approaches. In contrast, PARP inhibitors were also shown to have synthetic lethal interaction with loss of PTEN in cell culture (36, 37). If this interaction also occurs in breast tumors *in vivo*, then PARP inhibitors may still be effective in the majority of BRCA1-linked breast tumors characterized by PTEN loss and triple-negative subtype (evolutionary path 1), but not in the luminal subset (evolutionary path 2). Furthermore, as the frequency of *BRCA1* LOH is also higher in PTEN-null cases, the probability of efficient therapeutic response targeting BRCA1-null tumor cells (e.g., PARP inhibitors) is also expected to be higher in these cases than in the luminal subset. Second, our results also imply that AKT pathway inhibitors and agents designed for targeting p53 mutant tumor cells may show promise for the prevention and treatment of breast tumors in a subset of *BRCA1* mutation carriers. Finally, our methodology of single-cell profiling and computational identification of the evolutionary paths to tumorigenesis can also be applied to other tumor types and promises to provide information about the natural history of a range of human tumors.

METHODS

Tissue Samples and Cell Lines

Breast tissue samples were collected at Harvard-affiliated hospitals (Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Beth-Israel Deaconess Medical Center, Boston, MA), Seoul National University Bundang Hospital (Seoul, Korea), Texas Oncology-Baylor Charles A. Sammons Cancer Center (Dallas, TX), University of California San Francisco (San Francisco, CA), and Johns Hopkins University (Baltimore, MD) using protocols approved by the institutional review boards. Breast cancer cell lines used in the study were obtained from American Type Culture Collection (MDA-MB-468, MDA-MB-436, and HCC-1937), Marc Lippman (MCF7), and Steve Ethier (SUM149PT), and their identity confirmed by SNP6 array analysis. None of the cell lines were maintained as continuous cultures in the laboratory and were used only at early passage.

Immunohistochemistry

IHC was carried out using whole sections of FFPE tissues and antibodies for PTEN [Clone 138G6, rabbit monoclonal antibody (mAb); Cell Signaling], p53 (Clone DO-7, mouse mAb; Dako), and ER (Clone 6F11, mouse IgG1 mAb; Neomarkers). Heat-induced antigen retrieval was carried out in 10 mmol/L citric acid (pH = 6.0) in a steamer at 95°C for 40 minutes. Sections were incubated with primary antibodies diluted in 5% goat serum as follows: PTEN—1:100 dilution, overnight at 4°C, P53—1:100 dilution, 2 hours at room temperature, and ER—1:50 dilution, 3 hours at room temperature, followed by incubation with appropriate biotinylated secondary antibodies and peroxidase-conjugated avidin-biotin complexes (Elite ABC; Vector Laboratories). Formed immunocomplexes were visualized using diaminobenzidine (Sigma) or ImmPACT-VIP (Vector Laboratories). Sections were rinsed in PBS between each step. Double IHC was carried out by sequentially incubating the sections with PTEN and p53 or PTEN and ER antibodies. Peroxidase activity and nonspecific biotin binding were blocked by incubation with 3% hydrogen peroxide and 10% goat serum, respectively, between the sequential staining with the 2 different antibodies. Slides were counterstained with methyl green to visualize nuclei.

Immunofluorescence

Immunofluorescence was carried out using antibodies for BRCA1 (Clone MS110, mouse IgG1 mAb; Calbiochem), p53 (Clone DO-7, mouse mAb; Dako), Ki67 (clone MIB-1, mouse IgG1 mAb; Dako), PR (RB9017, rabbit polyclonal antibody; Neomarkers), polyglutamylated

tubulin (clone GT335, mouse IgG1 mAb; Enzo Life Sciences), and RAD51 (H-92, rabbit polyclonal antibody; Santa Cruz). Antigen retrieval, blocking, and primary antibody dilutions were the same as for IHC described above. Tissue sections were incubated with primary (BRCA1—1:100, 3 hours; RAD51—1:100, 3 hours) and secondary antibodies (Alexa Fluor 555-conjugated goat anti-mouse IgG1 and Alexa Fluor 488-conjugated goat anti-rabbit, both 1:100, 45 minutes; Invitrogen). Sections of normal breast tissue from 12 BRCA1 carriers and 9 noncarrier controls (with and without contralateral breast cancer) were stained using antibodies for polyglutamylated tubulin at 1:800 dilution for 1 hour at room temperature, or a combination of Ki67 and PR, at 1:100 dilution for 2 hours at room temperature. Alexa Fluor 555-conjugated goat anti-mouse IgG1 and Alexa Fluor 488-conjugated goat anti-rabbit secondary antibodies were used at 1:100 dilution and incubated for 45 minutes. Samples were washed twice with PBS-Tween 0.05% between incubations and protected for long-term storage with VECTASHIELD HardSet Mounting Medium with DAPI (catalog #H-1500; Vector Laboratories).

Immuno-FISH

A combination of immunofluorescence for p53 and FISH for BRCA1 was carried out essentially as previously described (38), but using probes specific for BRCA1 (BAC Clone ID: 831F13; Invitrogen) and chromosome 17 (CEP 17 Spectrum Green Probe; Abbott), and antibodies for p53 (Dako; Clone DO-7, mouse mAb). BRCA1 BAC probe was labeled by nick translation and Alexa Fluor 647-conjugated nucleotides (Abbott).

PIK3CA Mutation Analysis

DNA preparation and mutation analyses were carried out essentially as previously described (18); detailed procedures are available upon request.

Confocal Microscopy Analysis

Samples were stored at −20°C for at least 48 hours before image analysis. For combined PR and Ki67 immunofluorescence, different images from multiple areas of each sample were acquired with a Nikon Ti microscope attached to a Yokogawa spinning disk confocal unit, ×60 plan apo objective, and OrcaER camera controlled by Andor iQ software. For BRCA1 immunofluorescence and immuno-FISH, images were acquired with a SP5 Leica Confocal Microscope, ×60 plan objective, and analyzed by Leica software (Leica Application Suite—Advanced Fluorescence 2.2.0). For immuno-FISH, several images from different regions of each tumor were acquired by overlapping plans (Z-stack with 0.4-μm intervals) to capture all FISH signals in the section.

Scoring for the Expression of Markers in Individual Tumor Cells

For immuno-FISH, we analyzed 100 to 200 individual cancer cells from different areas of each tumor and scored the p53 status and the number of CEP and BAC probes in each cell. Because tumor cells that were positive or lacked PTEN were very well demarcated within tumors, PTEN status was defined by double-immunohistochemical staining of adjacent sections for PTEN and p53. Because double IHC provides a more complete overview of the section than immuno-FISH, a larger area was assessed by double IHC than by immuno-FISH. Thus, in small regions, we were able to assess PTEN and p53 but not BRCA1 status. These technical issues were taken into consideration during our statistical analyses by carrying out all possible permutations and selecting the weakest *P*-value (see details below). Similarly, because immunofluorescence is less sensitive than IHC, in a few cases we could not detect staining for mutant p53 by immunofluorescence, but still got good signal by IHC. In these cases, we counted the proportion of p53 mutant cells based on IHC and the BRCA1 status based on immuno-FISH slides and carried out all possible permutations and selected the weakest *P*-value (see details on next page).

For immunofluorescence for BRCA1 and polyglutamylated tubulin, we analyzed approximately 200 cells, whereas for Ki67 and PR double immunofluorescence, 1,000 to 2,000 cells were evaluated in each slide.

Comparison of BRCA1 LOH Based on FISH and PCR and Correlation between FISH and Immunofluorescence Data

To compare *BRCA1* LOH data based on PCR (14) to % LOH based on FISH we made the following assumptions: (i) there was no contamination from normal tissue/stroma; (ii) there was no copy gain or loss; (iii) both original and mutated tumor cell populations were homogeneous with respect to *BRCA1* locus. If these assumptions hold, then the *BRCA1* LOH PCR data can be expressed as $|(p-50)*2|$, in which P is the percentage of mutant allele. We used Somer D to analyze the concordance between FISH and immunofluorescence data.

Prediction of the Order of Events: BRCA1 LOH Status

BRCA1 LOH was determined using the ratio of copy number ratio of the BAC probe versus the CEP probe (centromeric) in each cell. Ideally a *BRCA1* wild-type cell should have a BAC to CEP ratio of 2:2 (referred to as BAC/CEP:2/2), whereas copy number alteration leads to a different ratio. Incidentally, the sectioning of tissue samples can affect nuclei of a subset of cells in a slide (e.g., those residing in the section plane) such that those cells have an apparently different BAC to CEP ratio even though they are genetically wild type. For example, during sectioning a wild-type cell may lose part of its nucleus, including one copy of chr17, leading to the BAC to CEP ratio of 1:1, which can be misinterpreted as loss of *BRCA1* due to whole chromosome loss during tumorigenesis. On the other hand, cells with *BRCA1* copy number alterations may have apparently normal BAC to CEP ratio for similar reasons. To estimate the bias introduced by the above phenomenon and to make necessary corrections in our analyses, we carried out a set of control analyses. We analyzed 15 independent slides prepared using *BRCA1* wild-type cells (MDA-MB-468 cell line), used as negative controls, and 15 independent slides prepared from cells with known *BRCA1* LOH (SUM-149, HCC-1937, and MDA-MB-436 cell lines), used as positive controls. The negative and positive control sets had approximately 35% and 3%, respectively, cells with BAC/CEP:2/2 ratios (Supplementary Table S3), as opposed to 100% and 0%, respectively, in the ideal case (Supplementary Table S3). Therefore, even a sample with only *BRCA1* wild-type cells would have about 65% cells with apparent signatures of *BRCA1* LOH (i.e., BAC/CEP \neq 2/2). The thickness of the slides had minimal effects on these proportions for both control sets. From the distribution of the proportions of BAC/CEP:2/2 cells in positive and negative control sets, we calculated the most probable number of cells present with genuine *BRCA1* LOH, after adjusting for the variability arising from the technical issue described above. We used a residual bootstrapping technique with 15 iterations. At each iteration, we drew a value (v_i ; $i = 1;15$) from the distribution of BAC/CEP:2/2 ratios in the negative control, and again one value (v_j ; $j = 1;15$) from the positive control. If, in a given slide, the proportion of cells with *BRCA1* LOH—with a certain status for PTEN and P53 genes—(i) was lower than v_i (the value expected to arise due to technical reasons), as observed in the negative control sets, we considered all those cells as wild type, and (ii) was higher than that v_j , we subtracted the contribution of variability due to technical reasons, and adjusted the number of *BRCA1* wild-type cells accordingly. We made similar adjustments based on the positive control set and recalibrated the number of cells with wild-type *BRCA1* and *BRCA1* LOH in the dataset. We then used the recalibrated dataset for further analysis. We also determined the order of events after adjustments using the median value of BAC/CEP:2/2, instead of the distribution of the proportion of BAC/CEP:2/2, in the positive and negative control sets. The order of events was highly similar to that depicted in Fig. 1 (Supplementary Table S4). To further validate this approach, we applied it to a set of slides derived from tissue blocks of different mixtures of cell lines with wild-type and mutant *BRCA1* (10%,

25%, and 40% of wild type and mutant mix). We then assessed correlations between estimated and known percentage using Somer D test.

Combinatorial Mutation Status

For a subset of the samples, it was difficult to determine the mutation status for multiple genes on a cell-by-cell basis, as we described above in the scoring section, because we used 2 sequential tissue sections to analyze the status of the 3 markers. To avoid any bias arising due to this ambiguity for each of those samples, we generated an ensemble of cases with cell counts for different combinations of the mutational status for the 3 genes, which satisfied the cell counts observed for individual mutations and their unambiguous combinations. Using a missing value imputation strategy, we then calculated a single P -value for the order of events in that sample from that ensemble of cases.

Order of Events

To determine the first event in a given sample, we compared the number of cells in the 3 groups: (i) PTEN loss, *BRCA1*, and P53 wild type (N100), (ii) P53 loss, *BRCA1*, and PTEN wild type (N010), and (iii) *BRCA1* gain (or loss), PTEN and P53 wild type (N001). We accepted the most abundant group to indicate the first mutation event and compared the number of cells in that group with each of the 2 others using a binomial test and then used the union–intersection test to obtain a conservative estimate:

$$P(PTEN) = \max \{F(N010, N100 + N010, 0.5), F(N001, N100 + N001, 0.5)\}$$

$$P(P53) = \max \{F(N100, N100 + N010, 0.5), F(N001, N010 + N001, 0.5)\}$$

$$P(BRCA1) = \max \{F(N100, N100 + N001, 0.5), F(N010, N001 + N010, 0.5)\}$$

in which

$$F(x, y, p) = \sum_{i=1}^n \binom{y}{x} p^x (1-p)^{y-x}$$

If 2 of the most abundant groups had the same number of cells, we flagged the first event as “unresolved.” Once the first mutation event was flagged, we compared the number of cells in the 2 groups, which (i) were mutated in the first and second gene and wild type for the third and (ii) wild type for the second gene and mutated in the first and third genes, using the binomial test as above. We generated an ensemble of instances for each sample to account for the technical variability described in the *BRCA1* LOH and combinatorial mutation status sections. Finally, using a missing value imputation strategy, we calculated a single P -value for the order of events in that sample from the ensemble of cases. If some cells had only one mutation and some other cells had only a different mutation, but no cells had both mutations, then the order of events was unclear. This scenario could potentially indicate 2 independent mutation events. Such cases are discussed as special cases.

Shannon and Simpson Indices of Diversity

Shannon and Simpson indices of diversity of *BRCA1* LOH were calculated following standard procedures (19) and as described previously (38). The Pearson correlation coefficient between Shannon and Simpson indices for our dataset (i.e., Supplementary Table S1) is -0.9186 . The anticorrelation is not surprising because a population with high Shannon index would usually have low Simpson index and vice versa.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank Drs. Pier Paolo Pandolfi for providing sections from *Pten*^{loxP/loxP}; *Pb-Cre4* mice, Stanislaw Weremowicz (Brigham and

Women's Hospital, Boston, MA) for her help with evaluation of metaphase FISH images, Lisa Cameron in the DFCI Confocal and Light Microscopy Core Facility for technical assistance, and David Pellman and Susana Godinho for their recommendation of antibodies to assess centrosomes, and also thank members of our laboratories for their critical reading of this manuscript and useful discussions.

Grant Support

This work was supported by the National Cancer Institute P50 CA89383 (to K. Polyak) and U54CA143798 (to F. Michor and M. Gönen), the Cellex foundation (to V. Almendro), Human Frontier Science Program long-term fellowship (to S. De), the Susan G. Komen Foundation (to K. Polyak and J. Garber), and the Breast Cancer Research Foundation (to K. Polyak, J. Garber, N. Tung, and S. Schnitt). The Programme for Advanced Medical Education (to F.C. Martins) is sponsored by Calouste Gulbenkian Foundation, Champalimaud Foundation, Ministério da Saúde and Fundação para a Ciência e Tecnologia, Portugal.

Received December 6, 2011; revised March 30, 2012; accepted April 4, 2012; published OnlineFirst April 10, 2012.

REFERENCES

- Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. *Nat Rev Cancer* 2007;7:937–48.
- Hemel D, Domchek SM. Breast cancer predisposition syndromes. *Hematol Oncol Clin North Am* 2010;24:799–814.
- Buchholz TA, Wu X, Hussain A, Tucker SL, Mills GB, Haffty B, et al. Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2. *Int J Cancer* 2002;97:557–61.
- Foray N, Randrianarison V, Marot D, Perricaudet M, Lenoir G, Feunteun J. Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2. *Oncogene* 1999;18:7334–42.
- Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, et al. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. *Proc Natl Acad Sci U S A* 2011;108:17773–8.
- Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. *Nat Med* 2009;15:907–13.
- Proia TA, Keller PJ, Gupta PB, Klebba I, Jones AD, Sedick M, et al. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. *Cell Stem Cell* 2011;8:149–63.
- Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH. Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. *Nat Genet* 1996;12:191–4.
- Goggins M, Hruban RH, Kern SE. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. *Am J Pathol* 2000;156:1767–71.
- Norquist BM, Garcia RL, Allison KH, Jokinen CH, Kernochan LE, Pizzi CC, et al. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. *Cancer* 2010;116:5261–71.
- King TA, Li W, Brogi E, Yee CJ, Gemignani ML, Olvera N, et al. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. *Ann Surg Oncol* 2007;14:2510–8.
- Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. *Nature* 2005;436:725–30.
- Saal LH, Gruvberger-Saal SK, Persson C, Lovgren K, Jomppanen M, Staaf J, et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. *Nat Genet* 2008;40:102–7.
- Tung N, Miron A, Schnitt SJ, Gautam S, Fettes K, Kaplan J, et al. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. *Breast Cancer Res* 2010;12:R95.
- Dean RB, Dixon WJ. Simplified statistics for small numbers of observations. *Anal Chem* 1951;23:636–8.
- Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. *Cancer Res* 2009;69:3625–33.
- Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. *Cancer Res* 2005;65:2554–9.
- Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, et al. PIK3CA mutations in *in situ* and invasive breast carcinomas. *Cancer Res* 2010;70:5674–8.
- Magurran AE. Measuring biological diversity. Malden: Blackwell; 2004.
- Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. *Cell* 1997;88:265–75.
- De Vargas Roditi L, Michor F. Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis. *J Theor Biol* 2011;273:207–15.
- Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. *Science* 2006;314:1467–70.
- Gagnon C, White D, Cosson J, Huitorel P, Edde B, Desbruyeres E, et al. The polyglutamylated lateral chain of alpha-tubulin plays a key role in flagellar motility. *J Cell Sci* 1996;109:1545–53.
- Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. *Nat Med* 2004;10:789–99.
- Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. *Cell* 2012;148:362–75.
- Attolini CS, Cheng YK, Beroukhi R, Getz G, Abdel-Wahab O, Levine RL, et al. A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. *Proc Natl Acad Sci U S A* 2010;107:17604–9.
- Durinck S, Ho C, Wang NJ, Jakkula LR, Collisson EA, et al. Temporal dissection of tumorigenesis in primary cancers. *Cancer Discov* 2011;1:137–43.
- Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci U S A* 1971;68:820–3.
- Hsu LC, White RL. BRCA1 is associated with the centrosome during mitosis. *Proc Natl Acad Sci U S A* 1998;95:12983–8.
- Sankaran S, Starita LM, Simons AM, Parvin JD. Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function. *Cancer Res* 2006;66:4100–7.
- Deng CX. Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice. *Mutat Res* 2001;477:183–9.
- Sankaran S, Starita LM, Groen AC, Ko MJ, Parvin JD. Centrosomal microtubule nucleation activity is inhibited by BRCA1-dependent ubiquitination. *Mol Cell Biol* 2005;25:8656–68.
- Li Y, Guessous F, Kwon S, Kumar M, Ibadapo O, Fuller L, et al. PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. *Cancer Res* 2008;68:1723–31.
- Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* 2005;434:917–21.
- Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. *Proc Natl Acad Sci U S A* 2008;105:17079–84.
- Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. *Sci Transl Med* 2010;2:53ra75.
- Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. *EMBO Mol Med* 2009;1:315–22.
- Park SY, Gönen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of *in situ* human breast carcinomas to an invasive phenotype. *J Clin Invest* 2010;120:636–44.